Publications

Wirth TC (2014) Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Rev Gastroenterol Hepatol 8(1):101-10.Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gürlevik E, Manns MP, Longerich T, Zender L, Harty JT, Kubicka S, Kühnel F, Wirth TC (2013) Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur J Immunol 44(4):1213-24.Woller N, Knocke S, Mundt B, Gürlevik E, Strüver N, Kloos A, Boozari B, Schache P, Manns MP, Malek NP, Sparwasser T, Zender L, Wirth TC, Kubicka S, Kühnel F (2011) Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 121(7):2570-82. Wirth TC, Martin MD, Starbeck-Miller G, Harty JT, Badovinac VP (2011) Secondary CD8+ T-cell responses are controlled by systemic inflammation. Eur J Immunol 41(5):1321-33.Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP (2010) Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity 33(1):128-40. Wirth TC, Harty JT, Badovinac VP (2010) Modulating numbers and phenotype of CD8+ T cells in secondary immune responses. Eur J Immunol 40(7):1916-26.Wirth TC Badovinac VP, Zhao L, Dailey MO, Harty JT (2009) Differentiation of central memory CD8 T cells is independent of CD62L-mediated trafficking to lymph nodes. J Immunol 182(10):6195-206.Wirth TC, Pham NL, Harty JT, Badovinac VP (2009) High initial frequency of TCR-transgenic CD8 T cells alters inflammation and pathogen clearance without affecting memory T cell function. Mol Immunol 47(1):71-8.Wirth T, Kühnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L, Kubicka S (2005) Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 65(16):7393-402.Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kühnel F (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63(12):3181-8.